JumpCode Genomics Raises $21M in Series B Financing Round

Jan 12, 2021

|

NEW YORK – Jumpcode Genomics said on Tuesday that it has raised $21 million in a Series B financing round.

The funding round was co-led by Baird Capital and Arboretum Ventures, and included existing investor LYZZ Capital.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.